Dear Friends,

When the Eye Research Institute was formally established in 2005 (named the McPherson Eye Research Institute in 2012), it was with the paramount goal of fostering collaboration among researchers in the many disciplines where vision research was being performed at UW-Madison. Ophthalmology, neuroscience, genetics, engineering, pediatrics, psychology, computer science, veterinary medicine, and two dozen other departments and schools all housed investigators who were working, directly or indirectly, on the visual system. For many researchers and clinicians who focused on blinding diseases, there was urgency in this collaboration, and recognition that the cures for devastating eye diseases and injuries would almost certainly come from cross-disciplinary advances. The McPherson ERI was formed to accelerate those collaborations.

Now, ten years later, you can measure our progress by our numerous and noteworthy member-researcher collaborations. A sample of those projects are highlighted on the opposite page, chosen from a broad range of work that addresses cutting-edge issues in diseases such as age-related macular degeneration, retinitis pigmentosa, glaucoma, and ocular cancer—as well as many projects that seek to understand other aspects of vision in both health and disease. We are in full flight toward becoming one of the most forward-thinking vision research centers in the world for current and future discovery. We have our researchers’ energy and focus to thank for this, and everyone who reads this report as well. The help that we have received from McPherson ERI supporters has been instrumental in boosting collaborative research, and we believe that you’ll be proud to share in the results—now and in years to come.

There is no one who represents the spirit of collaborative work better than our namesake and co-founder, Dr. Alice McPherson. Coincidentally, the 10th year of our Institute has given occasion for us to celebrate Dr. McPherson’s achievements in the company of many whom she has inspired. In May 2015, we were pleased to host a reception at the annual Association for Research in Vision and Ophthalmology (ARVO) conference in Denver, attended by a multitude of Dr. McPherson’s colleagues (including many former trainees) from around the world. It was a memorable occasion. In October 2015, she was honored by the University of Wisconsin-Madison—her alma mater for both bachelor and MD degrees—with the Distinguished Alumni Award, presented by Chancellor Rebecca Blank at her annual luncheon. That same day, Dr. McPherson met with students at her namesake learning community, McPherson House at the UW-Madison School of Medicine and Public Health. It is that meeting which sums up Dr. McPherson’s spirit and influence, in what has been a lifelong drive to foster and support education and research—whether among students, investigators, clinicians, or patients.

The McPherson Eye Research Institute has its roots in that drive and vision—and, as roots will do, they have grown into a network of full-sized collaborations. We anticipate many more to come, along with the groundbreaking results they engender, and we hope that you’ll continue with us on that journey.

David M. Gamm, MD, PHD

RRF Emmett A. Humble Distinguished Director
Sandra Lemke Trout Chair in Eye Research
ASSESSING SCLERAL COLLAGEN IN GLAUCOMA

A collaboration between veterinary ophthalmologist Dr. Gillian McLellan and engineer Dr. Jeremy Rogers aims to develop a new screening tool that could lead to improved outcomes in humans and animals with glaucoma. Their work explores the potential of assessing risk of blindness due to glaucoma by measuring light scattering from the sclera (tough outer coat that constitutes the white of the eye). Dr. McLellan’s studies in dogs and cats with glaucoma suggest that differences in individual susceptibility to high intraocular pressure, which results in optic nerve damage and blindness, may be linked to differences in the makeup of the sclera. It may be possible to use the light scattering properties of the sclera in a quick and simple test to identify those patients at most risk for vision loss from glaucoma, providing clinicians with a basis for more personalized care of individual patients.

ASSESSING VISUAL PATHWAYS IN AMBLYOPIA

Amblyopia (lazy eye) is a developmental visual disorder caused by poorly coordinated visual input to the two eyes. It disproportionately affects children of low socio-economic status, and if left untreated, leads to a number of visual deficits throughout adulthood. Using state-of-the-art neuroimaging techniques, Assistant Professor Bas Rokers and his graduate student, Brian Allen, recently established that these visual deficits are associated with structural abnormalities in several visual pathways in the human brain. These findings provide key insights into the neural consequences of amblyopia and provide novel avenues for diagnosis and treatment. The Rokers Lab is currently expanding upon this work, in a newly-formed collaboration with pediatric ophthalmologists at UW including Melanie Schmitt and Burton Kushner. To better understand the effects of amblyopia across the developmental trajectory, they are investigating the neuroanatomical consequences of successfully and unsuccessfully treated amblyopia.

Burton Kushner, MD & Melanie Schmitt, MD
Ophthalmology and Visual Sciences
Bas Rokers, PhD
Psychology

RETINAL REGENERATIVE MEDICINE

The University of Wisconsin-Madison is a world leader in stem cell research, and the McPherson Eye Research Institute has built upon this foundation to establish its own high-powered consortium of investigators in the field of retinal regenerative medicine. Anchored by Dr. James Thomson, who first developed the technology to grow human embryonic stem cells and later pioneered research into induced pluripotent stem cells, we have brought together top researchers to translate discovery to treatment: Dr. Gamm in generation of stem cell-based human retinal cells, including photoreceptors; Drs. Gong and Ma in design of 3-D retinal scaffolds for retinal cell delivery; Dr. Saha in stem cell gene editing and repair techniques; and Dr. Hei in future production of clinical grade retinal cells for patient use. Working together, these researchers are making strides to bring stem cell technology to patients with otherwise untreatable retinal diseases and injuries.

James Thomson, VMD, PhD
Director, Regenerative Biology
Morgridge Institute for Research

Derek Hei, PhD
Director, Biomannufacturing
Waisman Center

Krishanu Saha, PhD
Biomedical Engineering
Wisconsin Institute for Discovery

Zhenqiang Ma, PhD
Wisconsin Nano Engineering Device Lab
Electrical and Computer Engineering

David Gamm, MD, PhD
Director, McPherson ERI
Ophthalmology & Visual Sciences

Gillian McLellan, BVMS, PhD, DACVO
Ophthalmology and Visual Sciences; Veterinary Medicine

Jeremy D. Rogers, PhD
Biomedical Engineering

Shaoqin Gong, PhD
Biomedical Engineering
Wisconsin Institute for Discovery

PHOTO: SAHA LAB

ASSESSING VISUAL PATHWAYS IN AMBLYOPIA

Amblyopia (lazy eye) is a developmental visual disorder caused by poorly coordinated visual input to the two eyes. It disproportionately affects children of low socio-economic status, and if left untreated, leads to a number of visual deficits throughout adulthood. Using state-of-the-art neuroimaging techniques, Assistant Professor Bas Rokers and his graduate student, Brian Allen, recently established that these visual deficits are associated with structural abnormalities in several visual pathways in the human brain. These findings provide key insights into the neural consequences of amblyopia and provide novel avenues for diagnosis and treatment. The Rokers Lab is currently expanding upon this work, in a newly-formed collaboration with pediatric ophthalmologists at UW including Melanie Schmitt and Burton Kushner. To better understand the effects of amblyopia across the developmental trajectory, they are investigating the neuroanatomical consequences of successfully and unsuccessfully treated amblyopia.

Burton Kushner, MD & Melanie Schmitt, MD
Ophthalmology and Visual Sciences
Bas Rokers, PhD
Psychology

RETINAL REGENERATIVE MEDICINE

The University of Wisconsin-Madison is a world leader in stem cell research, and the McPherson Eye Research Institute has built upon this foundation to establish its own high-powered consortium of investigators in the field of retinal regenerative medicine. Anchored by Dr. James Thomson, who first developed the technology to grow human embryonic stem cells and later pioneered research into induced pluripotent stem cells, we have brought together top researchers to translate discovery to treatment: Dr. Gamm in generation of stem cell-based human retinal cells, including photoreceptors; Drs. Gong and Ma in design of 3-D retinal scaffolds for retinal cell delivery; Dr. Saha in stem cell gene editing and repair techniques; and Dr. Hei in future production of clinical grade retinal cells for patient use. Working together, these researchers are making strides to bring stem cell technology to patients with otherwise untreatable retinal diseases and injuries.

James Thomson, VMD, PhD
Director, Regenerative Biology
Morgridge Institute for Research

Derek Hei, PhD
Director, Biomannufacturing
Waisman Center

Krishanu Saha, PhD
Biomedical Engineering
Wisconsin Institute for Discovery

Zhenqiang Ma, PhD
Wisconsin Nano Engineering Device Lab
Electrical and Computer Engineering

David Gamm, MD, PhD
Director, McPherson ERI
Ophthalmology & Visual Sciences

Gillian McLellan, BVMS, PhD, DACVO
Ophthalmology and Visual Sciences; Veterinary Medicine

Jeremy D. Rogers, PhD
Biomedical Engineering

Shaoqin Gong, PhD
Biomedical Engineering
Wisconsin Institute for Discovery

PHOTO: SAHA LAB

ASSESSING VISUAL PATHWAYS IN AMBLYOPIA

Amblyopia (lazy eye) is a developmental visual disorder caused by poorly coordinated visual input to the two eyes. It disproportionately affects children of low socio-economic status, and if left untreated, leads to a number of visual deficits throughout adulthood. Using state-of-the-art neuroimaging techniques, Assistant Professor Bas Rokers and his graduate student, Brian Allen, recently established that these visual deficits are associated with structural abnormalities in several visual pathways in the human brain. These findings provide key insights into the neural consequences of amblyopia and provide novel avenues for diagnosis and treatment. The Rokers Lab is currently expanding upon this work, in a newly-formed collaboration with pediatric ophthalmologists at UW including Melanie Schmitt and Burton Kushner. To better understand the effects of amblyopia across the developmental trajectory, they are investigating the neuroanatomical consequences of successfully and unsuccessfully treated amblyopia.

Burton Kushner, MD & Melanie Schmitt, MD
Ophthalmology and Visual Sciences
Bas Rokers, PhD
Psychology

RETINAL REGENERATIVE MEDICINE

The University of Wisconsin-Madison is a world leader in stem cell research, and the McPherson Eye Research Institute has built upon this foundation to establish its own high-powered consortium of investigators in the field of retinal regenerative medicine. Anchored by Dr. James Thomson, who first developed the technology to grow human embryonic stem cells and later pioneered research into induced pluripotent stem cells, we have brought together top researchers to translate discovery to treatment: Dr. Gamm in generation of stem cell-based human retinal cells, including photoreceptors; Drs. Gong and Ma in design of 3-D retinal scaffolds for retinal cell delivery; Dr. Saha in stem cell gene editing and repair techniques; and Dr. Hei in future production of clinical grade retinal cells for patient use. Working together, these researchers are making strides to bring stem cell technology to patients with otherwise untreatable retinal diseases and injuries.

James Thomson, VMD, PhD
Director, Regenerative Biology
Morgridge Institute for Research

Derek Hei, PhD
Director, Biomannufacturing
Waisman Center

Krishanu Saha, PhD
Biomedical Engineering
Wisconsin Institute for Discovery

Zhenqiang Ma, PhD
Wisconsin Nano Engineering Device Lab
Electrical and Computer Engineering

David Gamm, MD, PhD
Director, McPherson ERI
Ophthalmology & Visual Sciences

Gillian McLellan, BVMS, PhD, DACVO
Ophthalmology and Visual Sciences; Veterinary Medicine

Jeremy D. Rogers, PhD
Biomedical Engineering

Shaoqin Gong, PhD
Biomedical Engineering
Wisconsin Institute for Discovery

PHOTO: SAHA LAB

ASSESSING VISUAL PATHWAYS IN AMBLYOPIA

Amblyopia (lazy eye) is a developmental visual disorder caused by poorly coordinated visual input to the two eyes. It disproportionately affects children of low socio-economic status, and if left untreated, leads to a number of visual deficits throughout adulthood. Using state-of-the-art neuroimaging techniques, Assistant Professor Bas Rokers and his graduate student, Brian Allen, recently established that these visual deficits are associated with structural abnormalities in several visual pathways in the human brain. These findings provide key insights into the neural consequences of amblyopia and provide novel avenues for diagnosis and treatment. The Rokers Lab is currently expanding upon this work, in a newly-formed collaboration with pediatric ophthalmologists at UW including Melanie Schmitt and Burton Kushner. To better understand the effects of amblyopia across the developmental trajectory, they are investigating the neuroanatomical consequences of successfully and unsuccessfully treated amblyopia.

Burton Kushner, MD & Melanie Schmitt, MD
Ophthalmology and Visual Sciences
Bas Rokers, PhD
Psychology

RETINAL REGENERATIVE MEDICINE

The University of Wisconsin-Madison is a world leader in stem cell research, and the McPherson Eye Research Institute has built upon this foundation to establish its own high-powered consortium of investigators in the field of retinal regenerative medicine. Anchored by Dr. James Thomson, who first developed the technology to grow human embryonic stem cells and later pioneered research into induced pluripotent stem cells, we have brought together top researchers to translate discovery to treatment: Dr. Gamm in generation of stem cell-based human retinal cells, including photoreceptors; Drs. Gong and Ma in design of 3-D retinal scaffolds for retinal cell delivery; Dr. Saha in stem cell gene editing and repair techniques; and Dr. Hei in future production of clinical grade retinal cells for patient use. Working together, these researchers are making strides to bring stem cell technology to patients with otherwise untreatable retinal diseases and injuries.

James Thomson, VMD, PhD
Director, Regenerative Biology
Morgridge Institute for Research

Derek Hei, PhD
Director, Biomannufacturing
Waisman Center

Krishanu Saha, PhD
Biomedical Engineering
Wisconsin Institute for Discovery

Zhenqiang Ma, PhD
Wisconsin Nano Engineering Device Lab
Electrical and Computer Engineering

David Gamm, MD, PhD
Director, McPherson ERI
Ophthalmology & Visual Sciences

Gillian McLellan, BVMS, PhD, DACVO
Ophthalmology and Visual Sciences; Veterinary Medicine

Jeremy D. Rogers, PhD
Biomedical Engineering

Shaoqin Gong, PhD
Biomedical Engineering
Wisconsin Institute for Discovery

PHOTO: SAHA LAB

ASSESSING VISUAL PATHWAYS IN AMBLYOPIA

Amblyopia (lazy eye) is a developmental visual disorder caused by poorly coordinated visual input to the two eyes. It disproportionately affects children of low socio-economic status, and if left untreated, leads to a number of visual deficits throughout adulthood. Using state-of-the-art neuroimaging techniques, Assistant Professor Bas Rokers and his graduate student, Brian Allen, recently established that these visual deficits are associated with structural abnormalities in several visual pathways in the human brain. These findings provide key insights into the neural consequences of amblyopia and provide novel avenues for diagnosis and treatment. The Rokers Lab is currently expanding upon this work, in a newly-formed collaboration with pediatric ophthalmologists at UW including Melanie Schmitt and Burton Kushner. To better understand the effects of amblyopia across the developmental trajectory, they are investigating the neuroanatomical consequences of successfully and unsuccessfully treated amblyopia.

Burton Kushner, MD & Melanie Schmitt, MD
Ophthalmology and Visual Sciences
Bas Rokers, PhD
Psychology
Along with environmental exposures, genetic variants contribute to our risk of disease. Dr. Brilliant’s research centers on the genetics behind vision disorders such as albinism, age-related macular degeneration (AMD), and glaucoma.

Albinism—although most often associated with the lack of melanin pigment in the iris, skin, and hair known as oculocutaneous albinism—may also be defined by eye conditions including underdevelopment of the central retina, poor visual acuity, nystagmus (repetitive uncontrolled eye movements), strabismus (eye misalignment), and misrouting of the optic nerves. Notably, AMD risk is highly correlated with pigmentation and affects the same tissues that fail to develop properly in albinism. A key factor underlying the visual defects in albinism is DOPA, a chemical intermediate in melanin biosynthesis. In all forms of oculocutaneous albinism, both pigment and DOPA are absent or severely reduced.

Individuals with ocular albinism (which causes the same ocular defects as all other forms of albinism, but is not associated with a severe reduction in visible pigmentation) lack the GPR143 gene, a receptor for DOPA. Under normal conditions, signaling through GPR143 increases endothelial growth factor (VEGF) — thereby slowing down, through two routes, the growth of blood vessels in the eye. In studying a vast cohort of individuals with and without AMD, Dr. Brilliant and his colleagues have found that AMD is delayed or absent in individuals taking L-DOPA. This implies that signaling through GPR143, via L-DOPA, may be used therapeutically to delay or prevent AMD.

Risk for age-related macular degeneration is largely inherited. In other work, Dr. Brilliant has leveraged analyses of over 20,000 DNA samples, combined with long-term medical records of the Marshfield Clinic’s Personalized Medicine Research Project, to determine the genetic risk factors for AMD and glaucoma. These data (stored in the genetic and clinical Data Warehouse pictured) have been crucial to advancing several national and international studies on the genetics of these ocular disorders.

At the Comparative Ocular Pathology Lab of Wisconsin (COPLOW), founded by Dick Dubielzig in 1983, animal eyes are studied as both a clinical priority—to help diagnose and treat animals with eye diseases—and as windows into complex questions of anatomy, morphology and visual function. A still-active emeritus professor in pathological sciences, Dr. Dubielzig served as COPLOW’s director for more than 30 years, amassing an extraordinary collection of ocular specimens from more than 570 species. In the course of this immersive study, Dubielzig has become one of the world’s foremost experts on the pathology and natural history of spontaneous diseases of the eye in animals, and has significantly advanced ocular comparative anatomy. His textbook *Veterinary Ocular Pathology: A Comparative Review* is a standard reference for pathologists and ophthalmologists seeking clarification on the nature of eye disorders.

Dr. Dubielzig recognized early on that COPLOW could serve as an international diagnostic center. Since its inception, more than 48,000 ocular specimens have been collected and archived, sent from dozens of institutions and veterinary ophthalmologists. Specimens are available as a teaching resource and have been used as principal research material by COPLOW trainees and other investigators. Dubielzig himself has authored almost 300 publications, primarily describing the morphologic changes in spontaneous animal diseases of the eye. Comparative study—discerning patterns, parallels or contrasts within and across species and breeds—has led him to first-time recognition of multiple ocular diseases.

Beyond the benefits that COPLOW brings to its home in the School of Veterinary Medicine, the laboratory plays an important role in the mutually informative and richly complementary study of animal and human eyes. Dick Dubielzig was the first veterinary faculty member to join the McPherson Eye Research Institute, and has been a pioneer in fostering collaboration between veterinary scientists and researchers in other schools at UW-Madison. Multiple cross-disciplinary studies have grown from this link, with results advancing understanding of eye health and disease in animals including humans.

In another study (*Human Mutations, July 2015*), the group located and identified a novel gene mutation responsible for blindness in children due to Leber congenital amaurosis (LCA16). This disease predominantly affects light sensitive photoreceptors or adjacent RPE cells, causing loss of vision. Pattnaik’s work has provided insight into the development of this disease using laboratory studies and gene manipulation in mice. In collaboration with David Gamm (Ophthalmology & Visual Sciences), De-Ann Pillers (Pediatrics) and others, his lab is now focusing on patient-derived iPSC cells ( induced pluripotent stem cells) to reproduce the disease phenotype at a cellular level, so that blindness-reversing candidate drugs can be easily tested through a disease-in-a-dish mechanism.
To develop new ways to prevent and treat cataracts, we need to understand the molecular mechanisms that direct lens morphogenesis and maintenance throughout life. Understanding begins with the composition of the lens. The transparency of the ocular lens relies, in part, on the precise hexagonal structure of the individual differentiated cells in the lens, called the fiber cells, and the packing of these cells to form the organized three-dimensional architecture of the lens. Disruption in fiber cell shape and lens structure leads to the loss of transparency and the formation of a cataract—which is the leading cause of blindness in the world today.

The current research objective in the laboratory of Professor Anne Griep, Department of Cell and Regenerative Biology, is to understand the molecular and genetic mechanisms that drive the formation of these unique fiber cells and the overall structure of the lens during embryonic and postnatal development. The lab uses the mouse as their model system because it is possible to generate mice carrying mutations in any gene of interest and then analyze the effects of that mutation on tissue development, structure and function.

Recent studies using genetically engineered mice have shown that in some organs, genes in the Wnt/Planar Cell Polarity (PCP) pathway are involved in dictating cell shape and the organization of cells into higher ordered structures. (PCP refers to polarity, or orientation, across a sheet of cells.) Dr. Griep’s lab recently identified the gene Discs large 1 (Dlg-1) as a previously unknown PCP gene in the mouse, and also learned that it is a requirement for fiber cell structure and differentiation. Her group found that in the lens, Dlg-1 interacts in unique ways with other known PCP genes to regulate the hexagonal shape of the fiber cells and signaling pathways that are required for fiber cell differentiation. Knowledge gained from these studies will contribute to the development of new strategies to prevent and treat cataracts and will enhance understanding of development and disease in other tissues and organs where PCP factors play a role.

Professor Rob Nickells and his lab study the molecular and cellular events associated with the death of retinal ganglion cells after optic nerve damage. This is the principal feature of diseases like glaucoma, which is rapidly becoming the leading cause of blindness in the world. His group studies the process of ganglion cell death using mouse models, work that they helped pioneer in the field of glaucoma research nearly two decades ago. Because the genome of these animals can be manipulated more easily than any other mammal, involving them in studies means that the functions of a variety of different genes can be directly tested in the cell death process.

The greatest focus of the Nickells group has been on the function of a single gene that regulates a form of cell death called “intrinsic apoptosis.” Deletion of this gene, called Bax, allows ganglion cells to survive indefinitely after damage induced both acutely to the nerve using surgery, or in a mouse model of glaucoma. A caveat to this promising strategy is that ganglion cells also undergo certain changes early in the cell death program that leave them in suspended animation, whether or not they have a functional Bax gene. The Nickells lab affectionately calls these cells “zombies.” Additional studies have concentrated on understanding the molecular changes the cells undergo to become zombies. Promising results have been obtained by targeting enzymes that modify the genome of dying cells early in the apoptotic process.

The overarching goal of Dr. Nickells’ research is to develop a way to specifically treat ganglion cells in glaucoma. This is paramount, since the only available treatment for this disease is to lower the intracocular pressure of an affected person. While effective for many, this treatment does not directly target the tissues that succumb to this disease, and for some, it is not enough to prevent continued vision loss. The Nickells lab hopes that combining pressure-lowering therapy with a strategy that directly protects ganglion cells will help preserve sight for all patients who have glaucoma.

Dr. Michael Nork, a vitreoretinal surgeon also trained in ophthalmic pathology, is interested in how ocular disease affects the retina in terms of both its morphology (form) and its electrophysiology (function). His laboratory focuses on outer retinal changes—specifically alteration in the rods and cones—that occur in glaucoma. Studying observed injury to rods and cones, previously underappreciated in the scientific literature, the Nork laboratory has found cone swelling and electrical changes suggestive of ischemia (lack of oxygen) in an animal model of glaucoma. While interesting from a basic science standpoint, such outer retinal changes per se are not the reason people with glaucoma lose vision. Rather, glaucoma patients go blind because the ganglion cells, whose axons connect the retina with the brain, gradually degenerate over the course of years. Why this occurs is not well understood, and leading theories involve either mechanical deformation of the optic nerve head or poor vascular supply to the optic nerve. However, neither theory explains the outer retinal effects.

As part of the effort to better understand any potential relationship between rod and cone injury in glaucoma and ganglion cell death, Dr. Nork’s lab has been studying a possible mechanism for this outer retinal injury—namely, decreased blood flow in the choroid, the layer of blood vessels supplying the rods and cones. His lab has developed a method to study regional choroidal blood flow with non-recirculating fluorescent microspheres (shown in figure). Using animal models of glaucoma, the Nork group has established that elevated eye pressure greatly decreases choroidal blood flow and could explain the injury seen in the rods and cones. By manipulating choroidal blood flow pharmacologically, Dr. Nork hopes that it will be possible to show a link between choroidal blood flow, outer retinal ischemia, and ganglion cell loss in glaucoma. If this proves to be the case, drugs that increase choroidal blood flow may represent an exciting new approach to saving vision in those who experience this common eye disease.
Professor Julie Mares and her team conduct research investigating nutrition and lifestyle in relation to risk for age-related cataract, macular degeneration, and diabetic retinopathy—providing evidence needed to develop strategies to prevent or slow these diseases. They have recently observed that people with a genetic predisposition for developing age-related macular degeneration (AMD) significantly reduced their odds of developing intermediate stages of this vision disorder if they smoked less than a pack a day for seven years, consistently ate a diet rich in fruits and vegetables, and exercised. Odds of developing AMD in those predisposed to this disease were also lowered if they maintained adequate blood levels of vitamin D. The overall findings suggest that one’s genes, diet, lifestyles, and vitamin D levels all come together in a synergistic way to mediate the disease processes that promote AMD.

In collaboration with Dr. Max Snodderly at the University of Texas, Dr. Mares’ primary research focus has been on the potential benefit of the yellowish dietary carotenoids, lutein and zeaxanthin, on eye health throughout the lifespan. In the coming year, in collaboration with Dr. Barbara Blodi (Ophthalmology & Visual Sciences), the Mares group will begin an NIH-funded project to provide the first epidemiological evidence to determine whether a low density of the dietary plant pigments (lutein and zeaxanthin) in the retina of the eye (macular pigment) predicts aging of the retina, development and progression of age-related macular degeneration, and loss of vision more than ten years later. In addition, they will evaluate whether aspects of diet, supplement use, lifestyle, health, and genetics help women maintain high macular pigment levels. This will be the longest-term large study of its type worldwide, and it will provide evidence as to whether a simple test to assess macular pigment levels via healthy lifestyles or via taking supplements.

The Mares group is also studying whether receiving lutein as early as infancy might enhance its accumulation over our lifetimes, suggesting that dietary standards for levels of lutein and zeaxanthin needed for optimal vision might be set for breastfeeding mothers and individuals of all ages.

Yevgenya Grinblat, PhD

Department of Zoology
College of Letters and Science

Neural retina, the “heart” of the eye, begins life as an integral part of the brain. Soon after fertilization, the brain undergoes a remarkable transformation from a flat sheet of cells to a tube-like structure, termed the neural tube. At the same time, the two retinal primordia emerge from the front end of the neural tube, coming to lie on either side of it. These future retinai remain connected to their place of origin via thin bridges called the optic stalks, precursors to the optic nerves that carry information from the eye back to the brain. The primordial retinae and optic stalk cells then engage in complex interactions with the surrounding tissues; it is through these interactions that the intricate visual apparatus (the eye) and its essential supporting tissues (muscles, blood vessels, cartilage and bones) emerge. The details of these cellular “conversations,” essential to the correct formation of the visual system, are largely unknown.

Professor Grinblat and her research group aim to identify genes that control these interactions and to explain how these genes act at the cellular level to bring about normal eye development. Their studies are focused on an early key step in retinal development, formation of the choroid fissure at the border of the retina closest to the optic stalk. Failure of choroid fissure formation leads to retinal coloboma, a birth defect that causes significant visual impairment. Importantly, the choroid fissure develops in close contact with a unique cellular milieu that includes cells fated to become facial skeleton and vasculature, and cross-lineage interactions contribute to choroid fissure formation in ways that are very poorly understood. This gap in our knowledge is largely due to a paucity of animal models in which to dissect the process.

To address the gap, the Grinblat lab is using cutting-edge genome engineering techniques to establish the zebrafish Zic2 mutant line as a genetic model of retinal coloboma. They will make full use of the extensive zebrafish researcher toolkit that includes genetics (i.e., mutagenesis and transgenesis), high-resolution live microscopy, and small molecule discovery tools. This work will identify novel genetic mechanisms involved in eye morphogenesis, paving the way for pharmaceutical strategies to alleviate retinal coloboma.
Within the Advanced Ocular Imaging Program at the Medical College of Wisconsin, co-directors and professors Alfredo Dubra and Joe Carroll focus on the development of novel technologies for ophthalmic imaging for advancing the understanding of eye disease, as well as accelerating and improving the evaluation of novel therapies. This requires using a highly interdisciplinary team with expertise in optical engineering, vision science, adaptive optics, computer science and computer engineering among other disciplines. Dr. Dubra’s work on ophthalmic adaptive optics instrumentation led to the non-invasive visualization of various microscopic retinal structures in the living eye, including the photoreceptor outer segment mosaic and the inner segment cone photoreceptor mosaic, capillary structure and perfusion and numerous pathological hyper-reflective structures.

In order to maximize the benefit of the technology and expertise generated in the group, the adaptive optics team is engaged in various long-term dissemination efforts with national and international research institutions. One of these efforts was recently recognized through one of the first Audacious Goals Initiative grants from the National Eye Institute. This project will advance major technological strides on adaptive optics ophthalmoscopes built at research institutions including the Medical College of Wisconsin, the University of Pennsylvania, University College London & Moorfields Eye Hospital, the New York Eye and Ear Infirmary, and Stanford University. One of the most exciting aspects of this team project is that all of the proposed technologies—such as advanced eye motion compensation and chromatic aberration correction—will be put to immediate use in photoreceptor gene therapy and neuroprotective clinical trials.

Dr. Dubra is also part of the Catalyst for a Cure Biomarkers Team supported by the Glaucoma Research Foundation, a collaborative group aiming to identify novel glaucoma biomarkers for early diagnosis and treatment monitoring.

The research group of Kristyn S. Masters in the Department of Biomedical Engineering is interested in creating 3-dimensional in vitro models of various diseases (i.e., “disease-in-a-dish”). In contrast to the usual goal of tissue engineering, which is to generate healthy tissues that may be used to repair or replace diseased tissues in a patient, Dr. Masters aims to generate engineered tissues that intentionally display disease characteristics. In creating such disease models, Dr. Masters has three goals: to elucidate the causes of various diseases; to understand why some patients are responsive to current treatments while others are not; and to identify new cellular and molecular events that may be targeted to prevent disease progression.

Research in the Masters Lab has generally focused upon cardiovascular diseases, specifically heart valve calcification. However, in recent years, Dr. Masters has been extending her tissue engineering–based disease research approach to investigate conditions related to abnormal growth of new blood vessels, or “pathological angiogenesis.” Pathological angiogenesis plays a significant role in numerous eye diseases, including age-related macular degeneration (AMD), which affects more than 30 million people worldwide. In late-stage, or “wet,” AMD, new vessels sprout from the existing microvasculature in the choroid layer of the retina, and these abnormal vessels leak fluid that damages the retina and causes acute vision loss.

Currently the Masters group is creating 3-D tissue-engineered models of the retinal environment in order to understand how different cells in the retina communicate with each other to regulate angiogenesis and to investigate how other microenvironmental features (e.g., the composition of the extracellular matrix that surrounds the cells) affect this process. In collaboration with Aparna Lakkaraju (Ophthalmology) and Pamela Kreeger (Biomedical Engineering), the ultimate goal of this work is to merge both experimental and computational approaches not only to better understand the process of AMD, but also to identify new therapeutic targets for improved AMD treatment.

As principal investigator for the NIH-funded PACT (Product Assistance for Cellular Therapy) Program, Dr. Hei leads a team that provides comprehensive support for cell therapy development including therapeutics derived from human embryonic/pluripotent stem cells and adult mesenchymal stem cells. Waisman Biomanufacturing coordinates efforts with select researchers and clinicians to advance the use of these cGMP cell banks for clinical applications, with a focus on the use of stem cells for treating heart, lung, and blood conditions or diseases.

Dr. Derek Hei is the Director of Waisman Biomanufacturing (WB), a specialized facility designed to manufacture cell and gene therapeutics for early-stage human clinical trials in compliance with the FDA’s current Good Manufacturing Practice (cGMP) guidelines. The state-of-the-art cleanroom facility is located at the Waisman Center. WB works with academic investigators to develop manufacturing processes and quality control methods and to provide overall product development and regulatory support that is critical to advancing novel biotherapeutics into human clinical trials. Waisman Biomanufacturing is capable of supporting the development of a wide range of biotherapeutics including gene therapeutics, cell therapeutics, vaccines, and recombinant proteins. This range of capabilities allows the facility to support research groups that are involved in developing complex, multi-component projects such as engineered stem cells.

WB recently initiated a collaborative project with Dr. David Gamm to develop a new cell therapy that may be used to treat retinal degenerative diseases. Using a differentiation process that was developed by the Gamm Lab, WB has produced cGMP-compliant induced pluripotent stem cells (iPSCs) that are differentiated into neural retinal progenitor cells and photoreceptor precursors. The team is currently working to optimize a manufacturing process and Quality Control test methods for iPSC-photoreceptor manufacturing to support future human clinical trials.

As principal investigator for the NIH-funded PACT (Product Assistance for Cellular Therapy) Program, Dr. Hei leads a team that provides comprehensive support for cell therapy development including therapeutics derived from human embryonic/pluripotent stem cells and adult mesenchymal stem cells. Waisman Biomanufacturing coordinates efforts with select researchers and clinicians to advance the use of these cGMP cell banks for clinical applications, with a focus on the use of stem cells for treating heart, lung, and blood conditions or diseases.
ENDOWED PROFESSORSHIPS AND CHAIRS AT THE MCPHERSON EYE RESEARCH INSTITUTE

David M. Gamm, MD, PhD
Director, McPherson Eye Research Institute

Retina Research Foundation Emmett A. Humble Distinguished Directorship
Modeling and Treating Retinal Disease with Human Induced Pluripotent Stem Cells (hiPSCs)

Sandra Lemke Trout Chair in Eye Research
Applications of stem cell technology to the study and treatment of age-related macular degeneration

Akihiro Ikeda, DVM, PhD
Associate Director, McPherson Eye Research Institute

Retina Research Foundation Walter H. Helmerich Research Chair
Identification of Genetic Factors Affecting Aging of the Retina

Christine M. Sorenson, PhD
Retina Research Foundation Daniel M. Albert Chair
Apoptosis in Retinal Vascular Development and Disease

Arthur S. Polans, PhD
Retina Research Foundation Kathryn and Latimer Murfee Chair
New Agents for the Treatment of Ocular Tumors and Neovascular Diseases of the Eye

Jeremy Rogers, PhD
Retina Research Foundation Edwin and Dorothy Gamewell Professor
Optical Instrumentation and Technology Platforms for the Study and Screening of Retinal Disease

Nansi J. Colley, PhD
Retina Research Foundation M. D. Matthews Research Professor
Molecular Genetic Studies of Retinal Degeneration in Drosophila

Aparna Lakkaraju, PhD
Retina Research Foundation Rebecca Meyer Brown Professor
Insight into the Cellular Basis of Retinal Degenerative Diseases

WITH GRATITUDE TO . . .

Alice R. McPherson, MD
Founder, President, and Scientific Director
Retina Research Foundation

Dr. Monroe Trout and Sandra Trout
McPherson Eye Visionaries
Sandra Lemke Trout Chair in Eye Research
Monroe & Sandra Trout Director’s Fund for Vision Research

MCPHERSON EYE RESEARCH INSTITUTE ADVISORY BOARD, 2014-2015

• Daniel M. Albert, MD, MS Founding Director, McPherson ERI
• Rose Barroilhet, Chair Director (retired), UW-Madison Space Management
• Darrell Behnke, JD Director, Private Client Reserve, U.S. Bancorp
• Petros E. Carvounis, MD Baylor College of Medicine
• Paul M. DeLuca, Jr, PhD Emeritus Provost, UW-Madison
• James E. Doyle, JD Foley & Lardner LLP; Governor (former), State of Wisconsin
• Kenneth Frazier Director (retired), UW-Madison General Library System
• Don R. Gray, PhD Vice-President (retired), UW Foundation
• Bruce E. Harville Office of Quality Improvement, UW-Madison
• Alice R. McPherson, MD President, Retina Research Foundation
• Sharon Madnek Owner, Say It Write
• Alan R. Morse, JD, PhD President & CEO, Lighthouse Guild
• Nell R. Ray Tax Consultant
• Harry Roth, MD Davis Duehr Dean (retired)
• David G. Walsh, JD Foley & Lardner LLP

HONORARY ADVISORY BOARD MEMBERS

• Oscar C. & Patricia Boldt The Boldt Company
• Derilyn Cattelino Philanthropist
• Erik Christianson External Affairs, NCAA
• Emmett A. Humble Retina Research Foundation Board of Directors
• Dr. Monroe & Sandra Trout Philanthropists

MCPHERSON EYE RESEARCH INSTITUTE LEADERSHIP COMMITTEE, 2014-2015

• Nansi Jo Colley, PhD School of Medicine and Public Health
• Kevin W. Eliceiri, PhD Graduate School; College of Engineering; Morgridge Institute for Research
• David M. Gamm, MD, PhD, Director School of Medicine and Public Health
• Akihiro Ikeda, DVM, PhD, Associate Director School of Medicine and Public Health
• Andrea H. Mason, PhD School of Education
• Gillian McLellan, BVMS, PhD, DACVO School of Veterinary Medicine; School of Medicine and Public Health
• Shiela I. Reaves, MA College of Agricultural and Life Sciences
• Vanessa R. Simmering, PhD College of Letters and Science
• Xiaojin (Jerry) Zhu, PhD College of Letters and Science
MANDELBAUM & ALBERT FAMILY VISION GALLERY
— SHOWCASING CONNECTIONS BETWEEN ART AND VISION

SEEING BEYOND DISABILITIES: UNIQUE INSIGHTS
January - May 2015
In partnership with the UW Waisman Center, VSA Wisconsin, and ArtWorking

BETWEEN THE IMAGINED & THE OBSERVED
June - August 2015
Paired photographic perspectives by UW Art Department artists —
Gregory Vershbow: Strange Specimens; Angela Johnson: Translation

2015 COOL SCIENCE IMAGE COMPETITION
September - December 2015
In partnership with UW Communications’ The Why Files
Sat, Mar 12th, 2016

Cycle for Sight 2016

Cycle for Sight

Our annual indoor cycling fundraiser took place in March 2015 at three locations – two Rec Sports facilities on the UW-Madison campus (the Nat and the SERF), and Madison’s west side Princeton Club. For an added bonus, friends of the McPherson ERI hopped on some bikes in Kuala Lumpur! Almost 200 riders had a great workout while raising funds for vision research at the Institute. Sincere thanks to all of our participants and supporters and to our major donors – Cellular Dynamics International, the Shopko Foundation, and the Princeton Club.

Visit cycleforsight.wisc.edu for further information.

3rd Annual McPherson ERI Endowed Lecture

Held May 18, 2015

Dr. Sheila Nirenberg
Weill Medical College, Cornell University

Professor Nirenberg shared her groundbreaking work in her lecture – Talking to the Brain in Its Own Language: Developing New Kinds of Prosthetic Devices. A MacArthur Foundation “Genius” Fellow, Nirenberg has discerned the neural code by which visual information captured by photoreceptor cells is converted to a pattern of electrical impulses in the brain, allowing us to “see.” She is developing a computerized eyeglass prosthetic that transmits coded information via the retinal ganglion cells to the brain, bypassing damaged photoreceptors. In early phases of clinical trials, this new strategy holds remarkable promise for treating blindness.

Next Spring – 4th Annual Lecture
April 28, 2016 – Dr. Pawan Sinha
WITH THANKS AND APPRECIATION

TO THE FOLLOWING $50+ CONTRIBUTORS TO THE MCPHERSON EYE RESEARCH INSTITUTE:

JULY 1, 2014 – NOVEMBER 1, 2015

- Michelle Acker
- Sanjay Agarwal
- Brittany Albaugh
- Daniel & Eleanor Albert
- Kathryn Allen
- Romesh Amarasingshe
- Ammar Ambuba
- Gary Anderson
- Jennifer Anderson
- Richard & Alice Appen
- Anne Appleton
- Anna Arrollo
- Jill Archer
- Mike Archer
- artcosience
- Robert Ayers
- Kathy Baillapowong
- Eric Bangerter
- Neal & Christine Barney
- Terri Baron
- Rose Barrollo
- Arthur Baryenbruch
- Diane Baryenbruch
- Mary Baryenbruch
- Anne & Kurt Bauer
- Thomas & Martha Beach
- Vicki Beglinger
- Darrell & Michelle Behrke
- Brian Beinborn
- Janet Belligan
- Sharon Bergeon
- Jean Bergman
- Susan Betbeze
- Ronald Bichik
- Oscar C. & Patricia Boldt
- The Boldt Company
- Anne Bolz
- Cindy Bong
- Karen Bosold
- Jill Bradshaw & Curtis Sower
- Rany Broomfield
- Robin Broomfield
- Cynthia Brower
- David & Teri Bruns
- LeGay Carter
- Petros Carvounis
- Delory & J. Anthony Cattellino
- Cellular Dynamics International, Inc
- Michael Chaim
- Christine Chambers
- Erik & Rachel Christiansen
- Robert Chritton
- Lisa Clark
- Paul Collins
- Mildred & Marvin Conney
- Betty Cooke
- John Court
- Amy Cushman
- Bill Caplewski
- Soesawati Darjatmoko
- Chandra Darjatmoko
- Laura Darjatmoko
- Matthew & Nancy Davis
- Deb DeMaster
- Lori Devine
- Direct Fitness Solutions
- Gary & Sherry Doering
- Chris Doering
- Tom & Suzanne Dow
- Jim & Jessica Doyle
- Derek Dreher
- Richard & Doris Dubielzig
- Marilyn Durst
- James Eells
- Erik’s Bike Shop
- Debbie Fairweather
- Ian & Dylan Fairweather
- Kaitlyn Fitzgerald
- Karl Fitzgerald
- Holly Fitzgerald
- Marshall & Lisa Fox
- Neil & Peggy Ford
- Jeanne Frank
- Kenneth Frazier
- Amy Fulton
- B’Ann Gabelt
- Jeffrey Galligan
- David & Marilyn Gamm
- Jodi Gerdes
- Angela Gerlach
- David Giles
- Mark Glade
- Kevin & Marcia Goecke
- David & Nancy Goode
- Kannan Govindasamy
- Niki Graham
- Judy & Steve Grahek
- Thomas & Christine Grannis
- Don & Joan Gray
- Paul & Elaine Greene
- Eric Groene
- Jane Gronden
- Kevin Guillikson
- Lian-Wung Guo & Hai Wu
- Charlotte Hagan
- Jeffrey Hanks
- Bruce Harville
- John Harrison
- Loretta Hemelsbach
- John & Virginia Hinderaker
- Susan Hind
- Sarah Huang
- Emmett A. Humble
- James Hunter
- Akitiho & Sakae Ikeda
- Naveen Iruiyaraj
- Susan Janara
- John H. Jensen
- Paul Jobst
- Richmond Johnson
- Sean Johnson
- Vicki Johnson
- Michael Johnson
- Sherry Kaiman
- Griffin Kaleop
- Margo & Kim Kaleop
- Jean Kalschur
- Christy & Chris Kaufman
- David Kerssey
- Sucha Khinna
- Daniel Kirch
- Patrick Kitzman
- Karen Konad
- Alexander Konad
- Kevin Krause
- William Krell
- Aparna Lakkaraju
- Susan Lefeber
- Jon Leuer
- Michelle Lindauer
- Daniel & Bettine Lipman
- Xiaohong Liu
- Wanda Lomprey
- Shana Longley
- Eric Luck
- Emily Luck
- Ralph Luck
- Madison Central Lions Club
- Madison Monona Lions Club
- Sharon Madnek
- Henry & Julie Malen
- Julie Mares
- Harold & Christine Mayer
- Peter McCormick
- Ryan McKadden
- McFarland Lions Club
- Tyler McKeever
- Gillian McClellan & Don Williams
- Tom & Kate McKahan
- Alice McPherson
- Kathy Michi
- Shigeru Midelfort
- Neil Miller
- Cherry Miller
- Nancy Mills
- Alan R. Morse
- Pamela Morton
- Carolyn & Charles Moskowy
- Anand Natamapalli
- Audrey Nelson
- Christin Nicomela
- Nicole Niebuhr
- Niko Instruments
- T. Michael Nork
- Mary O’Brien-Heinzen
- Kevin O’Connor
- Thomas O’Connor
- Ocular Services
- Ronald Olsen
- Oregon-Brookyn Lions Club
- Jill & Bill Oswald
- Bikash Pattrnkh
- Angela Pearson
- Bill & Kristin Pearson
- Tracy & Todd Perkins
- Mark Perona
- Suzanne Peyer
- Vassil Petychev
- Pfizer Inc
- Arthur S. Polans & Myra Schultz
- Mary & Mark Pribbenow
- Buss Price
- Eric Price
- The Princeton Club, Madison
- Paul Ratheau
- Neil & Harman Ray
- Division of Recreational Sports, UW-Madison
- Dianne Reddston
- Oliver & Genevieve Reddston
- Retina Research Foundation
- Chery Redfute
- Toni & Donald Richards
- Jean Roberts
- Thomas Roepke
- Jeremy & Kara Rogers
- Kristine Rose
- Harry & Karen Roth
- Ross Royster
- Julie Ruppert
- Katie Howarth Ryan
- Lynn Sarney
- Saris Cycling Group
- Alexandra Motala Scallion
- Katie Scallion
- Peggy Scallion & Mark Redston
- Ramona Scallion
- Sarah Scallion
- Rita Scallion
- Gregory & Shelly Scallion
- Kim Schmid
- Gayle Schmitt
- Diana & David Schumacher
- Donald Seidman
- Anna Shen
- Jane & Bill Shepard
- The Shoptko Foundation
- Patricia Sigler
- Jonathan Skarke & Emily Exten
- Jason Smith
- Benjamin Stein
- F. C. Steinbauer
- Brian Stillitad
- Leslie & Greg Stilton
- Mark Stilton
- Norman Stilson
- Gail & Richard Stirt
- Jodi & Alan Stout
- Sarah Sullivan
- Martha Sumi
- Joan Sumi
- Krishna Surapaneni
- Prasad Surapaneni
- Lisa Suter
- Tammy Swiftow
- James & Barbara Syverud
- TDS Telecommunications
- Marcia Thomas
- Alexandra Thomas
- Scott Thompson
- Carol Tellerfrud
- Jackye Toops
- Kimberly Toops
- Laura Toops
- Jon Torney
- Jerrel & David Torney
- Molly Torney
- Sandra & Monroe Trout
- Kevin Ulrich
- Amy & Steve Ulrich
- Julie Unite
- University Bookstore
- US Bancorp
- Nancy & Tim Valient
- Mackenzie & Brett Valient
- Connor Valient
- Debra & Daniel Valient
- Athene Valient
- Mike & Patricia Valient
- Thomas & Catherine Valient
- Paul & Elise Van Ginkel
- Erin Van Pay
- Eileen & Mark Van Pay
- Michael & Susan Van Sciden
- Verona Knights of Columbus #11155
- Edward Vidrak
- Connor Volker
- Fredrick & Colleen Volker
- Earl & Marlene Volkmann
- Walter Wally
- Abbey Walker
- David & Nancy Walsh
- Robert Walters
- Andrew & Judy Waterman
- Michael Weiden
- Frances Lipton Weinstein
- Esther Weiss
- Theodore & Nancy Widder
- Guilford Mitchell Wiley Jr.
- Robert & Carol Wilt
- Gina Wood
- Gerard Xavier
- James Yahr
- Ali Zarrinnam
- Xiaoizh Zhu
- David & Karen Zimmerman
- Rolland & Janet Zimmerman

THE MCPHERSON EYE RESEARCH INSTITUTE IS GRATEFUL FOR CONTRIBUTIONS AT ALL LEVELS OF SUPPORT!
MISSION STATEMENT:

The McPherson Eye Research Institute is a multidisciplinary community of scholars working to gain critical knowledge about the science and art of vision and apply it to the prevention of blindness.